Aktienanalyse zu Alnylam Pharmaceuticals, Inc. (ALNY)ALNYAlnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alnylam Pharmaceuticals appears to be a good buy at the current price of $231.83, especially considering its strong revenue growth of 74% year-over-year, reaching $1.17 billion in the latest quarter. The stock has also shown resilience, recovering approximately 25% since July, despite being down 35% year-to-date. The main risk is its high debt-to-equity ratio of 201.69%, which could affect financial stability if not managed properly.

18 analysts cover ALNY: 13 rate it Buy, 4 Hold and 1 Sell. The average price target is 479.53.